Well-Administered Coumadin No Worse for Mental Function Than Pradaxa, Study Finds
December 14th 2022Pradaxa (dabigatran) and Coumadin (warfarin) came out even in this randomized study. The Brazilian researchers who conducted the study said one explanation for the result is that use of Coumadin was exceptionally well managed because the patients were enrolled a study.
Read More
Some Mental Health Conditions Add to the Atrial Fibrillation Risk from Diabetes, Study Finds
December 9th 2022Korean study shows that depression, insomnia and anxiety add to the risk of atrial fibrillation among those with diabetes, according to a Korean study. Those mental health condition may affect the autonomic nervous system that regulates the heart. Bipolar disorder and schizophrenia did not increase the risk.
Read More
Weighing Ablation Options in Persistent, Large Atrium AF
November 14th 2022Researchers compared radiofrequency ablation, cryoballoon ablation and the thoracoscopic maze procedure. After adjustments for age and left atrium diameter, they found no prognostic differences among the treatment strategies for atrial fibrillation.
Read More
Investigators Report High Similarity Between NovoLog and Biosimilar Candidate
October 20th 2022A phase 3 trial sponsored by the biosimilar maker shows that its candidate, temporarily named MYL-1601D, has the same immunogenicity, efficacy and safety levels as NovoLog, Novo Nordisk’s brand-name insulin aspart. Novolog and its authorized generic currently have the U.S. insulin aspart market to themselves.
Read More
Study Provides Some Clues on How Smoking Might Lead to Atrial Fibrillation
October 17th 2022In mouse and other studies, University of South Florida researchers traced the effects of cigarette smoke on cardiac acetylcholine-activated inward rectifier potassium current, known as the heart’s 'pacemaker.'
Read More
Some Humira Biosimilar Customers Are Taking a Wait-and-See Approach
October 6th 2022Tom Newcomer, head of U.S. market access for Samsung Bioepis, maker of Hadlima, a Humira biosimilar, said some potential customers want to see which biosimilars will grab a large market share before deciding on which one to buy
Read More
Biosimilar Discontinuation Rates Are High But Comparable to Those for Reference Biologics: Review
September 14th 2022The review focused on Remicade (infliximab) and Enbrel (etanercept). The annualized discontinuation rate was 21% among patients who had undergone nonmedical switching to biosimilars. However, the rates were similar to those found in some separate analyses of patients on reference biologics.
Read More
The Holy Grail Search for Affordable Insulin: The Quest Continues
August 18th 2022The Inflation Reduction Act puts a $35 cap on monthly out-of-pocket expenses for insulin. The catch: It applies only to people covered by Medicare. Some states, including California, and Civica Rx, the generic drugmaker, are gearing up to make biosimilar versions of brand-name insulin products. The competition could drive down prices.
Read More
Enbrel Stays Above the Biosimilar Fray, but Humira Biosimilars May Nip at its Heels
June 15th 2022Amgen’s biologic won’t have biosimilar competition till 2029. But the possibility that up to 11 Humira biosimilars may come on the market in 2023 could exert some downward pressure on Enbrel’s price.
Read More